In Vitro Activity and Killing Effect of Uperin 3.6 against Gram-Positive Cocci Isolated from Immunocompromised Patients

Giacometti, Andrea; Cirioni, Oscar; Kamysz, Wojciech; Silvestri, Carmela; Licci, Alberto; D'Amato, Giuseppina; Nadolski, Piotr; Riva, Alessandra; Łukasiak, Jerzy; Scalise, Giorgio

doi:10.1128/aac.49.9.3933-3936.2005

Cited by 11 publications

(9 citation statements)

References 23 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 This was even more evident in the case of uperin 3.6 and aurein 1.2, whose MICs/MBCs were up to 16-fold higher than reported previously. 32,33 However, MICs/MBCs of uperin 3.6 and aurein 1.2 documented in a study of clinical isolates from skin infections were similar to those recorded in our series, 34 which implies that the activity of AMPs against S. aureus may be infection-specific. Lower susceptibility to AMPs among staphylococcal isolates being a subject of our study might also result from their adaptation to the specific microenvironment of CF airways.…”

supporting

confidence: 86%

Activity of antimicrobial peptides, alone or combined with conventional antibiotics, againstStaphylococcus aureusisolated from the airways of cystic fibrosis patients

2016

Self Cite

View full text Add to dashboard Cite

supporting

confidence: 86%

Activity of antimicrobial peptides, alone or combined with conventional antibiotics, againstStaphylococcus aureusisolated from the airways of cystic fibrosis patients

2016

Self Cite

View full text Add to dashboard Cite

“…It is one of the most potent membrane-active antimicrobial peptides isolated from amphibians [28]. The range of MICs for uperin 3.6 against our staphylococcal strains was similar to that in a study conducted by Giacometti on human S. aureus strains [29]. Unlike in studies of human S. aureus strains isolated from patients with cystic fibrosis and skin infections, uperin 3.6 turned out to be the most effective AMP against canine staphylococci [26,30].…”

Section: Discussionsupporting

confidence: 77%

In Vitro Efficiency of Antimicrobial Peptides against Staphylococcal Pathogens Associated with Canine Pyoderma

Jarosiewicz

Garbacz

Neubauer

et al. 2020

Animals

Self Cite

View full text Add to dashboard Cite

The emergence of staphylococcal canine pathogens resistant to multiple antimicrobial agents is a growing and urgent problem in veterinary practice. Antimicrobial peptides (AMPs) seem to be a promising alternative to conventional antibiotics. The aim of this in vitro study was to evaluate the antimicrobial activity of selected AMPs against pathogenic staphylococcal strains, including multidrug- and methicillin-resistant strains isolated from canine pyoderma cases. Seven antimicrobial peptides (aurein 1.2, CAMEL, citropin 1.1, protegrin-1, pexiganan, temporin A and uperin 3.6) synthesized by the 9-fluorenylmethoxycarbonyl (Fmoc) solid-phase method were tested. The minimal inhibitory and minimal bactericidal concentrations (MIC and MBC) were determined by the broth microdilution method. The study showed that analyzed AMPs exerted an extensive effect against canine pathogens, with the most active peptide being uperin 3.6. The tested AMPs were equally efficient against both resistant- and susceptible staphylococcal strains and were more efficient against Staphylococcus pseudintermedius than against Staphylococcus aureus strains. Our findings are particularly interesting from a clinical perspective, as they point to AMPs as potential therapeutic topical agents in canine pyoderma cases associated with antimicrobial resistance of staphylococci.

show abstract

“…MICs of these peptides were comparable to or higher than those of DEFA1 and eCATH1. Moreover, eCATH1 had bactericidal activity similar to that of vancomycin (median MBCs, 4 g/ml), used to treat rhodococcosis in humans, and a higher activity than rifampin and clarithromycin (median MBCs, 32 g/ml), commonly used to treat rhodococcosis in foals (17)(18)(19). As DEFA1 was more or less ineffective against the rhodococcosis-associated pathogen K. pneumoniae, eCATH1 appears to be more suitable in terms of therapeutic usage.…”

Section: Discussionmentioning

confidence: 95%

“…Giacometti et al (17)(18)(19) analyzed the activity of several AMPs as well as different conventional antibiotics in R. equi. MICs of these peptides were comparable to or higher than those of DEFA1 and eCATH1.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Potential of Equine DEFA1 and eCATH1 as Alternative Antimicrobial Drugs in Rhodococcosis Treatment

Schlusselhuber¹,

Jung

Bruhn³

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

f Rhodococcus equi, the causal agent of rhodococcosis, is a severe pathogen of foals but also of immunodeficient humans, causing bronchopneumonia. The pathogen is often found together with Klebsiella pneumoniae or Streptococcus zooepidemicus in foals. Of great concern is the fact that some R. equi strains are already resistant to commonly used antibiotics. In the present study, we evaluated the in vitro potential of two equine antimicrobial peptides (AMPs), eCATH1 and DEFA1, as new drugs against R. equi and its associated pathogens. The peptides led to growth inhibition and death of R. equi and S. zooepidemicus at low micromolar concentrations. Moreover, eCATH1 was able to inhibit growth of K. pneumoniae. Both peptides caused rapid disruption of the R. equi membrane, leading to cell lysis. Interestingly, eCATH1 had a synergic effect together with rifampin. Furthermore, eCATH1 was not cytotoxic against mammalian cells at bacteriolytic concentrations and maintained its high killing activity even at physiological salt concentrations. Our data suggest that equine AMPs, especially eCATH1, may be promising candidates for alternative drugs to control R. equi in mono-and coinfections.

show abstract

In Vitro Activity and Killing Effect of Uperin 3.6 against Gram-Positive Cocci Isolated from Immunocompromised Patients

Cited by 11 publications

References 23 publications

Activity of antimicrobial peptides, alone or combined with conventional antibiotics, againstStaphylococcus aureusisolated from the airways of cystic fibrosis patients

Activity of antimicrobial peptides, alone or combined with conventional antibiotics, againstStaphylococcus aureusisolated from the airways of cystic fibrosis patients

In Vitro Efficiency of Antimicrobial Peptides against Staphylococcal Pathogens Associated with Canine Pyoderma

In Vitro Potential of Equine DEFA1 and eCATH1 as Alternative Antimicrobial Drugs in Rhodococcosis Treatment

Contact Info

Product

Resources

About